Exchange: NASDAQ·Updated 02:40 PM EDT
News
all
press releases
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September Neurocrine Biosciences to Present at Upcoming Investor Conferences in September PR Newswire SAN DIEGO, Sept. 2, 2026 SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced...
PR Newswire
More News
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Zacks
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Zacks
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.
Zacks
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.
Zacks
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.
Zacks
Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'
Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported better-than-expected earnings. Rockwell Automation and Neurocrine Biosciences had mixed reactions from...
Benzinga
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?
Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessity support growth.
Zacks
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings
The Foundation for Prader-Willi Research has recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on VYKAT XR for fluid retention and related heart or breathing problems.
Stocktwits
What's Going On With Neurocrine Biosciences Stock On Wednesday?
Reports of serious adverse events and deaths linked to Neurocrine's VYKAT XR for Prader-Willi syndrome prompt caution.read more...
Benzinga

Advertisement|Remove ads.